Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

vTv Therapeutics (VTVT) Invested Capital (2016 - 2025)

vTv Therapeutics' Invested Capital history spans 12 years, with the latest figure at $64.4 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 428.22% year-over-year to $64.4 million; the TTM value through Dec 2025 reached $64.4 million, up 428.22%, while the annual FY2025 figure was $64.4 million, 428.22% up from the prior year.
  • Invested Capital for Q4 2025 was $64.4 million at vTv Therapeutics, down from $70.5 million in the prior quarter.
  • Across five years, Invested Capital topped out at $70.5 million in Q3 2025 and bottomed at -$56.3 million in Q1 2021.
  • The 5-year median for Invested Capital is -$9.1 million (2021), against an average of -$2.5 million.
  • The largest annual shift saw Invested Capital plummeted 196.54% in 2023 before it surged 428.22% in 2025.
  • A 5-year view of Invested Capital shows it stood at -$9.7 million in 2021, then dropped by 10.27% to -$10.7 million in 2022, then tumbled by 129.8% to -$24.7 million in 2023, then surged by 149.43% to $12.2 million in 2024, then soared by 428.22% to $64.4 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Invested Capital are $64.4 million (Q4 2025), $70.5 million (Q3 2025), and $2.4 million (Q2 2025).